7884 Report 2010 Report 2010 02 06 2010 17:38 Page 07 07 Business review BTG plc Annual Report and Accounts 2010 Business review Group highlights Report from the directors on the key strategic, financial and operational Revenue developments during the year.
08 Chairmans statement 98.5m 10 Chief Executive Ofcers review 08 09: 84.8m 14 Business review 22 Development pipeline 24 Principal risks and uncertainties Gross margin 28 Corporate responsibility 66.7% 08 09: 56.3% Operating profit 10.8m 08 09: 7.0m Operating profit is dened as the operating profit or loss before acquisition adjustments and reorganisation costs.
Cash and equivalents at 31 March 2010 82.6m 31 March 2009: 78.2m US commercial operations established Key hires made, agreements with contract support organisations in place CroFab and DigiFab sales and marketing plans in place Developing portfolio to leverage US commercial operations Targeting completion of Voraxaze Biologics License Application submission at end of 2010 Varisolve fide-risked and US Phase III trials to start Reviewing opportunities to acquire additional programmes and marketed products Integration of Protherics nearing completion On target to deliver 20m per annum cost savings Business processes reorganised Partnered programmes progressing towards regulatory submissions Campath Phase III trials in multiple sclerosis fully enrolled Otelixizumab first Phase III trial in type 1 diabetes enrolled, second has commenced enrolling Abiraterone acetate Phase III trials in prostate cancer ongoing BUSINESS REVIEW
